Smell Loss Therapy Research & Innovation at Cyrano Therapeutics
We are pioneering therapies like CYR‑064 to help patients regain their sense of smell and taste. Learn about our mission, scientific breakthroughs, and impact.
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop a therapy for people struggling with the loss of smell and flavor.
Our mission is to push the boundaries of medical science, bringing hope and healing to patients suffering from anosmia through advanced and effective smell loss therapy & treatments. With a team of world-class researchers and clinicians, Cyrano Therapeutics is at the forefront of smell loss therapy research and development, committed to delivering breakthroughs that matter.
We understand the profound impact that smell loss can have on quality of life. That’s why our dedicated research team is focused on creating therapies that restore this essential sense. By combining cutting-edge technology with compassionate care, we aim to offer patients a pathway to recovery and a renewed sense of smell.
At Cyrano Therapeutics, we believe in the power of science to change lives. Our ongoing commitment to innovation ensures that we remain leaders in the field of smell loss therapy, constantly seeking new ways to enhance patient outcomes and improve overall well-being.
Management Team
Krista Geoffrion
VP of Clinical Affairs
Krista has over 25 years of innovation experience in biotech and medical devices. She has been a pivotal early-stage contributor to cardiovascular, neuroscience, and women’s health technologies acquired by Bayer, Medtronic, and Stryker. Krista specializes in bridging the gap between medical breakthroughs and commercial scale.
Michael Lusty, PhD
Head of CMC
Michael has 25+ years experience in the development, approval and launch of nasal and inhalation products, including the nasal steroid Nasonex® while working at Schering-Plough, Azmacort® inhaler at Kos Pharmaceuticals/ Abbott and nasal midazolam, Nayzilam® for the treatment of seizure while at Ikano Therapeutics prior to its acquisition and launch by UCB.
Joe Smith
Head of Business Development
Joe has more than 20 years of biopharma experience across M&A, licensing, strategy, capital markets, and financing. Prior to his role with Cyrano, Joe led strategy and business development at Impel, OncoSec, EyePoint, Adare, Valeant, and Aton. Joe was also a consultant at Navigant and Easton Associates, as well as a biotech equity research associate at Bear Stearns and Lazard.
Michaela Kennedy
Controller
Michaela Kennedy is a seasoned strategic and operational business professional with a career spanning diverse industries and global markets in financial planning and analysis, cash flow management, mergers and acquisitions, and compliance. Michaela is a graduate of the University of Miami with an MBA in Investments & an MS in Intern. Business. She has held Series 7, 63, 65 securities licenses. She’s fluent in English and German.
Ron Kuppersmith, MD
Chief Clinical Advisor
Former President of the American Academy of Otolaryngology–Head and Neck Surgery. Currently the CEO of ENT Specialty Partners, former Board member of Spirox (acquired by Entellus), former Board advisor of Entellus (acquired by Stryker), and former Board Member of Arrinex (acquired by Stryker).
Board of Directors
Rick Geoffrion
Founder, President and CEO
& Board Member
With more than 35 years of management experience with pharmaceuticals and medical devices, Rick has led the company foundation of 7 healthcare companies. He currently sits on the Executive Committee for MDIC, a public/private partnership with FDA, CMS and the Healthcare industry. Rick is also a member of the External Advisory Board for the Cleveland Clinic Foundation
Gerry Brunk
Managing Director, Lumira Ventures
& Board Member
A Managing Director at Lumira Ventures, Gerry has more than 28 years of investment, consulting and entrepreneurial experience in the healthcare industry. Prior to joining Lumira Ventures in 2002, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities.
Taka Koda
Partner, Remiges Ventures
& Board Member
A Partner at Remiges Ventures, Taka has more than 20 years of business development and venture investment experience. Prior to joining Remiges Ventures, Taka spent 12 years with Mitsui’s Private Equity group where he held several board positions, held acting management roles in newly created companies and raised capital.
John Kollins
Biopharmaceutical Industry CEO
& Board Member
John has more than 30 years of biopharmaceutical industry experience and most recently served as the Co-founder President and CEO of Satsuma Pharmaceuticals, Inc., a company that developed a novel intranasal drug/device to treat migraine headaches. The company was sold to Shin Nippon Biomedical Laboratories in April 2023.
Jackson Streeter, MD
Limited Partner, DeepWork Capital
& Board Member
Dr. Streeter is currently the Director of UF Innovate Ventures at the University of Florida where he manages a venture fund for the Research Foundation. In addition, he manages life science investments for the Florida Opportunity Fund and DeepWork Capital where he is a limited partner. Dr. Streeter is also the inventor of over twenty patents and author on multiple scientific publications.
Our sense of smell is often taken for granted—until it’s gone. But beyond the ability to detect pleasant aromas or avoid foul ones, smell perception plays a profound role in how we experience the world. From triggering memories to shaping emotional responses, the olfactory system...
Read More
Press Release : Cyrano Therapeutics Announces the Launch of an Investigator-Initiated Clinical Study Evaluating CYR-064 for the Loss of Smell (Hyposmia) in Parkinson’s Disease Patients DELRAY BEACH, Fla., Feb. 4, 2025 /PRNewswire/ — Cyrano Therapuetics,inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss,...
Read More
Rick Geoffrion, Founder and CEO of Cyrano Therapeutics, is developing a drug to restore olfactory function due to post-viral loss of smell and taste. As a result of COVID-19, there has been a significant increase in the number of people affected by long-term smell and...
Read More
A Sense of Hope: Cyrano Therapeutics’ Mission to Restore Sense of Smell The sense of smell is an essential part of daily life, influencing how we enjoy food, connect with others, and stay safe in our environments. For millions of people worldwide, losing this critical...
Read More